Article

Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease

The Heart Hospital, 16-18 Westmoreland St, London W1G 8PH, UK
Heart (British Cardiac Society) (Impact Factor: 6.02). 08/2012; 98(19):1436-41. DOI: 10.1136/heartjnl-2012-302346
Source: PubMed

ABSTRACT To measure and assess the significance of myocardial extracellular volume (ECV), determined non-invasively by equilibrium contrast cardiovascular magnetic resonance, as a clinical biomarker in health and a number of cardiac diseases of varying pathophysiology.
Prospective study.
Tertiary referral cardiology centre in London, UK.
192 patients were mainly recruited from specialist clinics. We studied patients with Anderson-Fabry disease (AFD, n=17), dilated cardiomyopathy (DCM, n=31), hypertrophic cardiomyopathy (HCM, n=31), severe aortic stenosis (AS, n=66), cardiac AL amyloidosis (n=27) and myocardial infarction (MI, n=20). The results were compared with those for 81 normal subjects.
In normal subjects, ECV (mean (95% CI), measured in the septum) was slightly higher in women than men (0.273 (0.264 to 0.282 vs 0.233 (0.225 to 0.244), p<0.001), with no change with age. In disease, the ECV of AFD was the same as in normal subjects but higher in all other diseases (p<0.001). Mean ECV was the same in DCM, HCM and AS (0.280, 0.291, 0.276 respectively), but higher in cardiac AL amyloidosis and higher again in MI (0.466 and 0.585 respectively, each p<0.001). Where ECV was elevated, correlations were found with indexed left ventricular mass, end systolic volume, ejection fraction and left atrial area in apparent disease-specific patterns.
Myocardial ECV, assessed non-invasively in the septum with equilibrium contrast cardiovascular magnetic resonance, shows gender differences in normal individuals and disease-specific variability. Therefore, ECV shows early potential to be a useful biomarker in health and disease.

0 Followers
 · 
136 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Klinisches Problem Kardiomyopathien und Myokarditiden stellen im klinischen Alltag häufig eine Herausforderung hinsichtlich Differenzierung, Risikostratifizierung und Therapieführung dar. Es gibt zahlreiche Differenzialdiagnosen, die Erkrankungen betreffen häufig junge Patienten oder Menschen im mittleren Lebensalter, und ihr Verlauf ist sehr variabel – von asymptomatisch und nicht prognoserelevant bis zu plötzlichem Herztod oder schwerer Herzinsuffizienz bereits in jungen Jahren. Für die Prognose der Patienten ist es entscheidend wichtig, dass frühzeitig die richtige Diagnose gestellt und eine adäquate Behandlung eingeleitet wird. Therapeutische Standardverfahren Während für einige Formen von Kardiomyopathien kausale Therapieoptionen bestehen, kommen für den Großteil der Betroffenen allgemeine Maßnahmen der Herzinsuffizienz- und Devicetherapie in Frage. Andere wiederum benötigen keinerlei Intervention, jedoch aufmerksames Monitoring. Diagnostik Die Diagnosestellung einer Kardiomyopathie basiert überwiegend auf dem kardialen Phänotyp. Daher kommt der nichtinvasiven Bildgebung eine besondere Bedeutung zu. Die kardiovaskuläre Magnetresonanztomographie hat sich zum Goldstandard bei der Beurteilung von Kardiomyopathien entwickelt. Sie vereint funktionelle Informationen (z. B. Wandbewegung) mit der myokardialen Gewebeanalyse (z. B. Fibrose, Ödem). In einigen Fällen kann sie daher die invasive endomyokardiale Biopsie ersetzen. Leistungsfähigkeit Die besondere Bedeutung der kardiovaskulären Magnetresonanztomographie zur Beurteilung von Kardiomyopathien beruht auf: akkurate Analyse kardialer Dimension und Funktion; nichtinvasive Gewebeanalyse zur Diagnosestellung (z. B. Myokarditis); Prognoseabschätzung mittels nichtinvasiver Gewebeanalyse; hohe Reproduzierbarkeit für valide Verlaufskontrollen, Potenzial für technische Weiterentwicklungen (z. B. Quantifizierung des Extrazellulärvolumens mittels T1-Mapping). Bewertung Die kardiovaskuläre Magnetresonanztomographie kann bei allen Formen von Kardiomyopathien die Differenzierung, Risikostratifizierung und Therapieführung beeinflussen. Bei einigen Formen ist der Einsatz in der klinischen Praxis bereits durch Evidenz belegt (z. B. Myokarditis), bei anderen deuten erste Ergebnisse zukünftiges Potenzial an (z. B. Risikostratifizierung bei hypertropher Kardiomyopathie). Empfehlung für die Praxis Die kardiovaskuläre Magnetresonanztomographie hat sich zum Goldstandard bei der Beurteilung von Kardiomyopathien entwickelt, da sie funktionelle und morphologische Informationen über das Myokard vereint. Es wird empfohlen, diese Technik bei Kardiomyopathien in einem umfassenden diagnostischen Ansatz zu verwenden.
    Der Radiologe 01/2012; 53(1). DOI:10.1007/s00117-012-2380-6 · 0.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Myocardial extracellular volume (ECV) is elevated in fibrosis or infiltration and can be quantified by measuring the haematocrit with pre and post contrast T1 at sufficient contrast equilibrium. Equilibrium CMR (EQ-CMR), using a bolus-infusion protocol, has been shown to provide robust measurements of ECV using a multibreath-hold T1 pulse sequence. Newer, faster sequences for T1 mapping promise whole heart coverage and improved clinical utility, but have not been validated. METHODS: Multibreathhold T1 quantification with heart rate correction and single breath-hold T1 mapping using Shortened Modified Look-Locker Inversion recovery (ShMOLLI) were used in equilibrium contrast CMR to generate ECV values and compared in 3 ways.Firstly, both techniques were compared in a spectrum of disease with variable ECV expansion (n=100, 50 healthy volunteers, 12 patients with hypertrophic cardiomyopathy, 18 with severe aortic stenosis, 20 with amyloid). Secondly, both techniques were correlated to human histological collagen volume fraction (CVF%, n=18, severe aortic stenosis biopsies). Thirdly, an assessment of test:retest reproducibility of the 2 CMR techniques was performed 1 week apart in individuals with widely different ECVs (n=10 healthy volunteers, n=7 amyloid patients). RESULTS: More patients were able to perform ShMOLLI than the multibreath-hold technique (6% unable to breath-hold). ECV calculated by multibreath-hold T1 and ShMOLLI showed strong correlation (r2=0.892), little bias (bias -2.2%, 95%CI -8.9% to 4.6%) and good agreement (ICC 0.922, range 0.802 to 0.961, p<0.0001). ECV correlated with histological CVF% by multibreath-hold ECV (r2= 0.589) but better by ShMOLLI ECV (r2= 0.685). Inter-study reproducibility demonstrated that ShMOLLI ECV trended towards greater reproducibility than the multibreath-hold ECV, although this did not reach statistical significance (95%CI -4.9% to 5.4% versus 95%CI -6.4% to 7.3% respectively, p=0.21). CONCLUSIONS: ECV quantification by single breath-hold ShMOLLI T1 mapping can measure ECV by EQ-CMR across the spectrum of interstitial expansion. It is procedurally better tolerated, slightly more reproducible and better correlates with histology compared to the older multibreath-hold FLASH techniques.
    Journal of Cardiovascular Magnetic Resonance 12/2012; 14(1):88. DOI:10.1186/1532-429X-14-88 · 5.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Cardiac magnetic resonance (CMR) T1 mapping has been used to characterize myocardial diffuse fibrosis. The aim of this study is to determine the reproducibility and sample size of CMR fibrosis measurements that would be applicable in clinical trials. Methods A modified Look-Locker with inversion recovery (MOLLI) sequence was used to determine myocardial T1 values pre-, and 12 and 25min post-administration of a gadolinium-based contrast agent at 3 Tesla. For 24 healthy subjects (8 men; 29 ± 6 years), two separate scans were obtained a) with a bolus of 0.15mmol/kg of gadopentate dimeglumine and b) 0.1mmol/kg of gadobenate dimeglumine, respectively, with averaged of 51 ± 34 days between two scans. Separately, 25 heart failure subjects (12 men; 63 ± 14 years), were evaluated after a bolus of 0.15mmol/kg of gadopentate dimeglumine. Myocardial partition coefficient (λ) was calculated according to (ΔR1myocardium/ΔR1blood), and ECV was derived from λ by adjusting (1-hematocrit). Results Mean ECV and λ were both significantly higher in HF subjects than healthy (ECV: 0.287 ± 0.034 vs. 0.267 ± 0.028, p=0.002; λ: 0.481 ± 0.052 vs. 442 ± 0.037, p < 0.001, respectively). The inter-study ECV and λ variation were about 2.8 times greater than the intra-study ECV and λ variation in healthy subjects (ECV:0.017 vs. 0.006, λ:0.025 vs. 0.009, respectively). The estimated sample size to detect ECV change of 0.038 or λ change of 0.063 (corresponding to ~3% increase of histological myocardial fibrosis) with a power of 80% and an alpha error of 0.05 for heart failure subjects using a two group design was 27 in each group, respectively. Conclusion ECV and λ quantification have a low variability across scans, and could be a viable tool for evaluating clinical trial outcome.
    Journal of Cardiovascular Magnetic Resonance 12/2012; 14(1):90. DOI:10.1186/1532-429X-14-90 · 5.11 Impact Factor
Show more